These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29735469)

  • 1. Drug effect of atorvastatin on middle cerebral atherosclerotic stenosis and high resolution NMR diagnosis.
    Chen X; Wang S; Lin L; Li Y; Zhang H
    Pak J Pharm Sci; 2018 May; 31(3(Special)):1169-1173. PubMed ID: 29735469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
    Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
    Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    Rader DJ; Davidson MH; Caplan RJ; Pears JS
    Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy comparison of rosuvastatin and atorvastatin in the treatment of atherosclerosis and drug safety analysis.
    Liping Z; Xiufang L; Tao Y; Baomin Z; Houshuai T
    Pak J Pharm Sci; 2018 Sep; 31(5(Special)):2203-2208. PubMed ID: 30463813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
    Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison and analysis of the therapeutic effect of different statins in the treatment of atherosclerosis.
    Liu M; Liu G; Wang M
    Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1737-1742. PubMed ID: 30203772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
    Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
    Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study.
    Welty FK; Lewis SJ; Friday KE; Cain VA; Anzalone DA
    J Womens Health (Larchmt); 2016 Jan; 25(1):50-6. PubMed ID: 26539650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
    Blasetto JW; Stein EA; Brown WV; Chitra R; Raza A
    Am J Cardiol; 2003 Mar; 91(5A):3C-10C; discussion 10C. PubMed ID: 12646336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
    Cheung RC; Morrell JM; Kallend D; Watkins C; Schuster H
    Int J Cardiol; 2005 Apr; 100(2):309-16. PubMed ID: 15823640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type.
    Kim J; Kim HS; Yang W; Lee JW; Kang HT
    Int J Environ Res Public Health; 2020 Aug; 17(17):. PubMed ID: 32872631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
    Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
    Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment.
    Ruiz-Iruela C; Padró-Miquel A; Pintó-Sala X; Baena-Díez N; Caixàs-Pedragós A; Güell-Miró R; Navarro-Badal R; Jusmet-Miguel X; Calmarza P; Puzo-Foncilla JL; Alía-Ramos P; Candás-Estébanez B
    PLoS One; 2018; 13(10):e0205430. PubMed ID: 30304062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
    Deedwania PC; Hunninghake DB; Bays HE; Jones PH; Cain VA; Blasetto JW;
    Am J Cardiol; 2005 Feb; 95(3):360-6. PubMed ID: 15670545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg.
    Stein B; Ward T; Hale G; Lyver E
    Ann Pharmacother; 2020 May; 54(5):405-413. PubMed ID: 31718234
    [No Abstract]   [Full Text] [Related]  

  • 18. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis.
    Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
    Eur J Prev Cardiol; 2016 May; 23(7):744-7. PubMed ID: 26246463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome.
    Bener A; Dogan M; Barakat L; Al-Hamaq AO
    J Prim Care Community Health; 2014 Jul; 5(3):180-7. PubMed ID: 24522932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.